464 related articles for article (PubMed ID: 25948185)
21. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
22. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
[TBL] [Abstract][Full Text] [Related]
24. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
26. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Signorovitch J; Ayyagari R; Reichmann WM; Wu EQ; Chen L
Cancer Treat Rev; 2014 Mar; 40(2):285-92. PubMed ID: 24112812
[TBL] [Abstract][Full Text] [Related]
27. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
[TBL] [Abstract][Full Text] [Related]
28. [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase].
Yin H; Chen LF; Cui JK; Xiong YY; You Y; Zou P; Li WM
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):810-815. PubMed ID: 29136709
[No Abstract] [Full Text] [Related]
29. [Analysis of the Curative Effect and Influencing Factors of Nilotinib Second-line and Dasatinib Third-line on Chronic Myelogenous Leukemia Failed First-line and Second-line Treatment].
Liu Q; Xu J; Wu J; Zhang XL; Qiu HC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):30-35. PubMed ID: 35123600
[TBL] [Abstract][Full Text] [Related]
30. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Wang J; Shen ZX; Saglio G; Jin J; Huang H; Hu Y; Du X; Li J; Meng F; Zhu H; Hu J; Wang J; Hou M; Hertle S; Menssen HD; Ortmann CE; Tribouley C; Yuan Y; Baccarani M; Huang X
Blood; 2015 Apr; 125(18):2771-8. PubMed ID: 25766724
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
[TBL] [Abstract][Full Text] [Related]
32. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
[TBL] [Abstract][Full Text] [Related]
34. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
35. Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia.
Chen Y; Yin H; Chen L; Xiong Y; Meng L; Guo J; Wang H; Li W
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e43-e49. PubMed ID: 31902734
[TBL] [Abstract][Full Text] [Related]
36. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Fava C; Kantarjian HM; Jabbour E; O'Brien S; Jain N; Rios MB; Garcia-Manero G; Ravandi F; Verstovsek S; Borthakur G; Shan J; Cortes J
Blood; 2009 May; 113(21):5058-63. PubMed ID: 19282457
[TBL] [Abstract][Full Text] [Related]
37. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
[TBL] [Abstract][Full Text] [Related]
39. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
40. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Griffin JD; Guerin A; Chen L; Macalalad AR; Luo J; Ionescu-Ittu R; Wu EQ
Curr Med Res Opin; 2013 Jun; 29(6):623-31. PubMed ID: 23517347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
